PE20190337A1 - NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN - Google Patents

NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN

Info

Publication number
PE20190337A1
PE20190337A1 PE2018000410A PE2018000410A PE20190337A1 PE 20190337 A1 PE20190337 A1 PE 20190337A1 PE 2018000410 A PE2018000410 A PE 2018000410A PE 2018000410 A PE2018000410 A PE 2018000410A PE 20190337 A1 PE20190337 A1 PE 20190337A1
Authority
PE
Peru
Prior art keywords
branched
independently
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
PE2018000410A
Other languages
English (en)
Inventor
Andrea Fiumana
Nicolas Foloppe
Stuart Ray
David Walmsley
Andras Kotschy
Michael Frank Burbridge
Francisco Humberto Cruzalegui
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20190337A1 publication Critical patent/PE20190337A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Referido a un compuesto de formula (I), en la que R1 y R2, independientemente uno de otro, representa H, halogeno, -NR5R5' o un grupo alquilo(C1-C6) lineal o ramificado, entre otros; W3 es un alcoxi (C1-C6) lineal o ramificado, -O-alquileno(C0-C6)-Cy1, entre otros; W4 es ciano, cicloalquilo, alquilo(C1-C6) lineal o ramificado, entre otros; R5 y R5', cada uno independientemente de los otros, es H, o un grupo alquilo(C1-C6) lineal o ramificado; a1 y A2, cada uno, independientemente del otro, es CH o un atomo de nitrogeno; Cy1, Cy2 y Cy3, independientemente uno de otro, es cicloalquilo, un grupo heterocicloalquilo, grupo arilo o un heteroarilo. Un compuesto seleccionado es: 5-(2-aminopiridin-4-il)-N-(2-metoxibencil)-2-metil-7H-pirrolo[2,3-d]pirimidin-4-amina. Tambien se refiere a un proceso para su preparacion, composiciones farmaceuticas que los contienen y a su uso en el tratamiento del cancer, trastornos neurodegenerativos o trastornos metabolicos.
PE2018000410A 2015-09-30 2016-09-30 NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN PE20190337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Publications (1)

Publication Number Publication Date
PE20190337A1 true PE20190337A1 (es) 2019-03-07

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000410A PE20190337A1 (es) 2015-09-30 2016-09-30 NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN

Country Status (26)

Country Link
US (1) US20180273538A1 (es)
EP (1) EP3356364A1 (es)
JP (1) JP2018533552A (es)
KR (1) KR20180054856A (es)
CN (1) CN108137582A (es)
AU (1) AU2016333508A1 (es)
BR (1) BR112018005851A2 (es)
CA (1) CA2999937A1 (es)
CL (1) CL2018000786A1 (es)
CO (1) CO2018003466A2 (es)
CR (1) CR20180176A (es)
CU (1) CU20180027A7 (es)
DO (1) DOP2018000082A (es)
EA (1) EA201890820A1 (es)
EC (1) ECSP18023286A (es)
FR (1) FR3041640B1 (es)
HK (1) HK1255467A1 (es)
IL (1) IL258231A (es)
MA (1) MA43021A (es)
MX (1) MX2018003861A (es)
NI (1) NI201800042A (es)
PE (1) PE20190337A1 (es)
PH (1) PH12018500605A1 (es)
SV (1) SV2018005656A (es)
TN (1) TN2018000087A1 (es)
WO (1) WO2017055533A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
TW202330533A (zh) * 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途
WO2023064349A1 (en) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093264B2 (en) 2005-05-20 2012-01-10 Methylgene Inc. Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
KR20080063837A (ko) 2005-10-13 2008-07-07 글락소 그룹 리미티드 Ｓｙｋ 억제제로서의 피롤로피리미딘 유도체
WO2007104944A1 (en) 2006-03-11 2007-09-20 Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives used as hsp90 inhibitors
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
JP6487921B2 (ja) * 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン

Also Published As

Publication number Publication date
CN108137582A (zh) 2018-06-08
WO2017055533A1 (en) 2017-04-06
CU20180027A7 (es) 2018-07-05
TN2018000087A1 (en) 2019-07-08
CR20180176A (es) 2018-05-31
CO2018003466A2 (es) 2018-07-10
MA43021A (fr) 2018-08-08
NI201800042A (es) 2018-06-21
FR3041640A1 (es) 2017-03-31
US20180273538A1 (en) 2018-09-27
ECSP18023286A (es) 2018-04-30
AU2016333508A1 (en) 2018-04-12
JP2018533552A (ja) 2018-11-15
EP3356364A1 (en) 2018-08-08
MX2018003861A (es) 2018-08-16
CL2018000786A1 (es) 2018-09-28
HK1255467A1 (zh) 2019-08-16
KR20180054856A (ko) 2018-05-24
DOP2018000082A (es) 2018-10-15
CA2999937A1 (en) 2017-04-06
IL258231A (en) 2018-05-31
BR112018005851A2 (pt) 2018-10-09
SV2018005656A (es) 2018-08-10
EA201890820A1 (ru) 2018-10-31
PH12018500605A1 (en) 2018-09-24
FR3041640B1 (fr) 2019-05-17

Similar Documents

Publication Publication Date Title
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CU24393B1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
BR112015027381A2 (pt) pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
PH12016501440A1 (en) Novel heterocyclic compounds
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
ES2667477T3 (es) Compuestos heterobiciclo-sustituidos-[1,2,4]triazolo[1,5-c]quinazolin-5-amina adecuados para el tratamiento o la prevención de trastornos del sistema nervioso central
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR078786A1 (es) Derivados de la cromenona
PE20180356A1 (es) Derivados de etinilo como moduladores del receptor metabotropico del glutamato
AR065901A1 (es) Derivados de pirrolipirimidina
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR088449A1 (es) Benzilindazoles sustituidos